Tapinarof
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB06083 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 13 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | primary release disorder of platelets | KG + DL |
| 2 | pseudo-von Willebrand disease | KG + DL |
| 3 | dermatitis | KG + DL |
| 4 | Glanzmann thrombasthenia | KG + DL |
| 5 | acne keloid | KG + DL |
| 6 | neonatal dermatomyositis | KG + DL |
| 7 | amyopathic dermatomyositis | KG + DL |
| 8 | secondary interstitial lung disease specific to childhood associated with a connective tissue disease | KG + DL |
| 9 | acrodermatitis chronica atrophicans | KG + DL |
| 10 | hydroa vacciniforme, familial | KG + DL |
| 11 | HER2 positive breast carcinoma | KG + DL |
| 12 | chromhidrosis | KG + DL |
| 13 | fetal and neonatal alloimmune thrombocytopenia | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.